Wird geladen...
Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
Background: Wixela(®) Inhub(®) was developed to deliver inhaled fluticasone propionate/salmeterol (FP/S) combination as a substitutable generic equivalent to Advair(®) Diskus(®). These studies aimed to confirm the pharmacokinetic bioequivalence (BE) of FP/S after single doses of Wixela Inhub (test [...
Gespeichert in:
| Veröffentlicht in: | J Aerosol Med Pulm Drug Deliv |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Mary Ann Liebert, Inc., publishers
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7041328/ https://ncbi.nlm.nih.gov/pubmed/31364911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jamp.2019.1537 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|